Patient characteristics
Characteristics . | MEL100 . | MP . |
---|---|---|
No. | 95 | 99 |
Age | ||
Median age, y | 65 | 63 |
Range, y | 51-70 | 52-70 |
65 or older, % | 46.3 | 36.4 |
Gender | ||
Male, no. (%) | 51 (54) | 54 (55) |
Female, no. (%) | 44 (46) | 45 (45) |
Stage | ||
IIA, no. (%) | 34 (36) | 32 (32) |
IIB, no. (%) | 3 (3) | 5 (5) |
IIIA, no. (%) | 53 (56) | 58 (58) |
IIIB, no. (%) | 5 (5) | 4 (4) |
Median β2-microglobulin, nM/L (mg/L) | 246.5 (2.9) | 246.5 (2.9) |
β2-microglobulin | ||
Less than 255 nM/L, no. (%) | 37 (39) | 40 (40) |
At least 255 nM/L, no. (%) | 46 (48) | 37 (37) |
Data missing, no. (%) | 12 (13) | 22 (22) |
M-protein class | ||
IgG, no. (%) | 64 (67) | 59 (60) |
IgA, no. (%) | 22 (23) | 27 (27) |
Bence Jones protein, no. (%) | 8 (9) | 11 (11) |
Others, no. (%) | 1 (1) | 2 (2) |
Characteristics . | MEL100 . | MP . |
---|---|---|
No. | 95 | 99 |
Age | ||
Median age, y | 65 | 63 |
Range, y | 51-70 | 52-70 |
65 or older, % | 46.3 | 36.4 |
Gender | ||
Male, no. (%) | 51 (54) | 54 (55) |
Female, no. (%) | 44 (46) | 45 (45) |
Stage | ||
IIA, no. (%) | 34 (36) | 32 (32) |
IIB, no. (%) | 3 (3) | 5 (5) |
IIIA, no. (%) | 53 (56) | 58 (58) |
IIIB, no. (%) | 5 (5) | 4 (4) |
Median β2-microglobulin, nM/L (mg/L) | 246.5 (2.9) | 246.5 (2.9) |
β2-microglobulin | ||
Less than 255 nM/L, no. (%) | 37 (39) | 40 (40) |
At least 255 nM/L, no. (%) | 46 (48) | 37 (37) |
Data missing, no. (%) | 12 (13) | 22 (22) |
M-protein class | ||
IgG, no. (%) | 64 (67) | 59 (60) |
IgA, no. (%) | 22 (23) | 27 (27) |
Bence Jones protein, no. (%) | 8 (9) | 11 (11) |
Others, no. (%) | 1 (1) | 2 (2) |